Underlying pathways for interferon risk to type II diabetes mellitus

Current Diabetes Reviews

Volumn 9, Issue 6, 2013, Pages 472-477

  Abdel Hamid, Nabil ^a   Al Jubori, Taghreed ^b   Farhan, Amaal ^b   Mahrous, Mariam ^c   Gouri, Adel ^d   Awad, Ezzat ^e   Breuss, Johannes ^e  

^a KAFRELSHEIKH UNIVERSITY   (Egypt)

^b MIDDLE TECHNICAL UNIVERSITY   (Iraq)

^c MINIA UNIVERSITY   (Egypt)

^d Ibn Zohr hospital   (Algeria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti inflammatory; Diabetes mellitus; HCV; Inflammatory mediators; Molecular mediators

Indexed keywords

ALPHA INTERFERON; GLUCOSE; GLUCOSE TRANSPORTER; INSULIN RECEPTOR SUBSTRATE 1; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE; PROTEASOME; STAT PROTEIN; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNE DISEASE; COMORBIDITY; CYTOTOXICITY; DIABETOGENESIS; DISEASE PREDISPOSITION; DOWN REGULATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEPATITIS C; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR;

ANTIVIRAL AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERFERON-ALPHA; INTERLEUKIN-1; MALE; PATIENT SELECTION; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893002903     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/15733998113096660080     Document Type: Article

References (70)

1. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39: 1005-1029.
2. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002; 5: 551-559.
3. Munzberg H, Myers MG, Jr. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 2005; 8: 566-570.
4. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
5. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973.
6. Lu L, Li C, Fu Y, et al. Complete genomes for hepatitis C virus subtypes 6f, 6i, 6j and 6m: viral genetic diversity among Thai blood donors and infected spouses. J Gen Virol 2007; 88: 1505-1518.
7. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
8. Galossi A, Guarisco R, Bellis L, et al. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 2007; 16: 65-73.
9. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-333.
10. Mehta S, Levey JM, Bonkovsky HL. Extrahepatic manifestations of infection with hepatitis C virus. Clin Liver Dis 2001; 5: 979-1008.
11. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599.
12. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama 2001; 286: 327-334.
13. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002; 23: 831-834.
14. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32 Suppl 3: 24-34.
15. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003; 14: 447-455.
16. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
17. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992; 130: 43-52.
18. Hotamisligil GS, Budavari A, Murray D, et al. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994; 94: 1543-1549.
19. Cheung AT, Wang J, Ree D, et al. Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes 2000; 49: 810-819.
20. Ruan H, Hacohen N, Golub TR, et al. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002; 51: 1319-1336.
21. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614.
22. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus downregulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508.
23. Aytug S, Reich D, Sapiro LE, et al. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-1392.
24. Pazienza V, Clement S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-1171.
25. Haruta T, Uno T, Kawahara J, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000; 14: 783-794.
26. Rui L, Yuan M, Frantz D, et al. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002; 277: 42394-42398.
27. Zaitseva, II, Hultcrantz M, Sharoyko V, et al. Suppressor of cytokine signaling-1 inhibits caspase activation and protects from cytokine-induced beta cell death. Cell Mol Life Sci 2009; 66: 3787-3795.
28. Kasai D, Adachi T, Deng L, et al. HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. J Hepatol 2009; 50: 883-894.
29. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11, 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47.
30. Waguri M, Hanafusa T, Itoh N, et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract 1994; 23: 33-36.
31. Foulis AK, Farquharson MA, Meager A. Immunoreactive alphainterferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987; 2: 1423-1427.
32. Fabris P, Floreani A, Tositti G, et al. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003; 18: 549-558.
33. Uto H, Matsuoka H, Murata M, et al. A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy. Diabetes Res Clin Pract 2000; 49: 101-106.
34. Soultati AS, Dourakis SP, Alexopoulou A, et al. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13: 1292-1294.
35. Stewart TA, Hultgren B, Huang X, et al. Induction of type I diabetes by interferon-alpha in transgenic mice. Science 1993; 260: 1942-1946.
36. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291.
37. Bottazzo GF, Dean BM, McNally JM, et al. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985; 313: 353-360.
38. Foulis AK. Interferon-alpha and IDDM: comment. Diabetologia 1996; 39: 127.
39. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992; 340: 548.
40. Seifarth C, Benninger J, Bohm BO, et al. Augmentation of the immune response to islet cell antigens with development of diabetes mellitus caused by interferon-alpha therapy in chronic hepatitis C]. Z Gastroenterol 1999; 37: 235-239.
41. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38: 641-647.
42. Starr R, Willson TA, Viney EM, et al. A family of cytokineinducible inhibitors of signalling. Nature 1997; 387: 917-921.
43. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387: 921-924.
44. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924-929.
45. Hilton DJ, Richardson RT, Alexander WS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A 1998; 95: 114-119.
46. Larsen L, Ropke C. Suppressors of cytokine signalling: SOCS. Apmis 2002; 110: 833-844.
47. Chong MM, Thomas HE, Kay TW. gamma-Interferon signaling in pancreatic beta-cells is persistent but can be terminated by overexpression of suppressor of cytokine signaling-1. Diabetes 2001; 50: 2744-2751.
48. Santangelo C, Scipioni A, Marselli L, et al. Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines. Eur J Endocrinol 2005; 152: 485-489.
49. Matsumoto A, Masuhara M, Mitsui K, et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997; 89: 3148-3154.
50. Saito H, Morita Y, Fujimoto M, et al. IFN regulatory factor-1-mediated transcriptional activation of mouse STAT-induced STAT inhibitor-1 gene promoter by IFN-gamma. J Immunol 2000; 164: 5833-5843.
51. Auernhammer CJ, Bousquet C, Melmed S. Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc Natl Acad Sci U S A 1999; 96: 6964-6969.
52. Yasukawa H, Misawa H, Sakamoto H, et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. Embo J 1999; 18: 1309-1320.
53. Nicholson SE, Willson TA, Farley A, et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. Embo J 1999; 18: 375-385.
54. Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokineinducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. Embo J 1995; 14: 2816-2826.
55. Zhang JG, Farley A, Nicholson SE, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A 1999; 96: 2071-2076.
56. Verdaguer J, Schmidt D, Amrani A, et al. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J Exp Med 1997; 186: 1663-1676.
57. Chong MM, Chen Y, Darwiche R, et al. Suppressor of cytokine signaling-1 overexpression protects pancreatic beta cells from CD8+ T cell-mediated autoimmune destruction. J Immunol 2004; 172: 5714-5721.
58. Flodstrom-Tullberg M, Yadav D, et al. Target cell expression of suppressor of cytokine signaling-1 prevents diabetes in the NOD mouse. Diabetes 2003; 52: 2696-2700.
59. Karlsen AE, Ronn SG, Lindberg K, et al. Suppressor of cytokine signaling 3 (SOCS-3) protects beta-cells against interleukin-1beta-and interferon-gamma-mediated toxicity. Proc Natl Acad Sci U S A 2001; 98: 12191-12196.
60. Karlsen AE, Heding PE, Frobose H, et al. Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1beta-mediated toxicity through inhibition of multiple nuclear factor-kappaB regulated proapoptotic pathways. Diabetologia 2004; 47: 1998-2011.
61. Flodstrom M, Maday A, Balakrishna D, et al. Target cell defense prevents the development of diabetes after viral infection. Nat Immunol 2002; 3: 373-382.
62. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
63. Hong F, Nguyen VA, Gao B. Tumor necrosis factor alpha attenuates interferon alpha signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy. FASEB J 2001; 15: 1595-1597.
64. Bode JG, Ludwig S, Ehrhardt C, et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. Faseb J 2003; 17: 488-490.
65. Sobue S, Nomura T, Ishikawa T, et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J Gastroenterol 2001; 36: 544-551.
66. Tian Z, Shen X, Feng H, et al. IL-1 beta attenuates IFN-alpha betainduced antiviral activity and STAT1 activation in the liver: involvement of proteasome-dependent pathway. J Immunol 2000; 165: 3959-3965.
67. Taylor DR, Shi ST, Romano PR, et al. Inhibition of the interferoninducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-110.
68. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
69. Gough DJ, Sabapathy K, Ko EY, et al. A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. J Biol Chem 2007; 282: 938-946.
70. Cacciarelli TV, Martinez OM, Gish RG, et al. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre-and posttreatment with interferon alfa. Hepatology 1996; 24: 6-9.